SCHEMBL7164972

SCHEMBL7164972

Cc1c(Cl)cccc1Nc1ccccc1CC(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCL8 P10145 5/20 0.75
▸ PTGS2 P35354 7/20 0.71
▸ TTR P02766 4/20 0.71
▸ MT-CO2 P00403 3/20 0.71
▸ ADRA1A P35348 2/20 0.71
▸ AKR1B10 O60218 1/20 0.71
▸ UGT1A9 O60656 1/20 0.71
▸ TRPA1 O75762 1/20 0.71
▸ ABCB11 O95342 1/20 0.71
▸ ALB P02768 1/20 0.71
▸ UGT1A6 P19224 1/20 0.71
▸ UGT1A1 P22309 1/20 0.71
▸ PTGS1 P23219 1/20 0.71
▸ CXCR1 P25024 1/20 0.71
▸ AGTR2 P50052 1/20 0.71
▸ NR1I3 Q14994 1/20 0.71
▸ SLC22A6 Q4U2R8 1/20 0.71
▸ NR1H4 Q96RI1 1/20 0.71
▸ UGT1A7 Q9HAW7 1/20 0.71
▸ UGT1A10 Q9HAW8 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11561045 0.87 P2RX7 (0.57) CXCL8PTGS2TTRMT-CO2ADRA1A
SCHEMBL6243911 0.86 CXCL8 (1.00) CXCL8PTGS2TTRMT-CO2ADRA1A
SCHEMBL11563738 0.86 CXCL8 (0.67) CXCL8PTGS2TTRMT-CO2ADRA1A
SCHEMBL11560050 0.86 PTGS2 (0.56) CXCL8PTGS2TTRMT-CO2ADRA1A
SCHEMBL11563426 0.86 MT-CO2 (0.56) CXCL8PTGS2TTRMT-CO2ADRA1A
SCHEMBL7162418 0.85 PTGS2 (0.75) CXCL8PTGS2TTRMT-CO2ADRA1A
SCHEMBL6258193 0.85 CXCL8 (0.79) CXCL8PTGS2TTRMT-CO2ADRA1A
SCHEMBL8956419 0.83 PTGS2 (0.54) CXCL8PTGS2TTRMT-CO2ADRA1A
Diclofenac SCHEMBL29354260 0.83 PTGS2 (1.00) CXCL8PTGS2TTRMT-CO2ADRA1A
Diclofenac SCHEMBL996716 0.83 PTGS2 (1.00) CXCL8PTGS2TTRMT-CO2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552077-B2 Kidney disorders EXOCELL, INC. 2003-04-22 — — US disclosed
EP-1242069-A2 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL, INC. (US) 2002-09-25 — — EP disclosed
US-6355680-B1 BLOCKING REACTION OF GLUCOSE AND ALBUMIN EXOCELL, INC. 2002-03-12 — — US disclosed
US-20010034359-A1 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies EXOCELL, INC. 2001-10-25 — — US disclosed
WO-2001003684-A2 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL, INC. (US) 2001-01-18 — — WO disclosed
US-4173577-A ANTICOAGULANTS; ANTIINFLAMMATORY AGENTS; ANTIPYRETICS; ANALGESICS CIBA-GEIGY CORPORATION (US) 1979-11-06 — — US disclosed
US-4092430-A ANTICOAGULANTS, ANALGESTIC, ANTIPYRETIC ACTIVITY CIBA-GEIGY CORPORATION (US) 1978-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034359-A1 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies ALB, AGER, TTR CXCL8 3032/4885PTGS2 2067/4885TTR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback